Pediatrix Medical Group, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $MD in the last 7 days.
Pediatrix Medical Group (MD) reported Q2 revenue growth to $487.8M and adjusted EPS of $0.63, up from $0.53. Growth was driven by pricing and share buybacks, not patient volume, which declined. Costs rose in some areas, and the company reaffirmed its full-year EBITDA guidance of $280M-$300M.
Pediatrix Medical Group (MD) officer Mary Ann E. Moore filed a Rule 144 notice to sell 21,335 shares, valued at $572,619.71, through Merrill Lynch on the NYSE. The shares stem from vested stock awards, with 81,253,271 shares outstanding as of September 11, 2026. Moore previously sold 9,260 shares in August 2026.
Linynsky Laura A sold (to issuer) 6,000 shares of Pediatrix Medical Group, Inc. (MD) at $26.82 ($0.16M total) on 2026-09-10.
Recent MD coverage spans financial news, earnings and insider activity.
In the last 30 days, MD insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($161K). The most active reporter was Linynsky Laura A with 1 filing.
Earnings beat on EPS and revenue despite declining patient volumes; buyback reduces share count, supporting near-term price.
The disclosed insider sale adds modest supply pressure and may signal limited confidence from the officer.
Minor insider sale by a director; unlikely to move price materially.
A small insider sale filing that could modestly increase share supply.
No new corporate event; the piece is a valuation commentary that may influence short‑term sentiment.
AlphAI scores every news story that mentions MD with an AI model for sentiment and relevance, and aggregates insider trades from Pediatrix Medical Group, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Pediatrix Medical Group (MD) reported Q2 revenue growth to $487.8M and adjusted EPS of $0.63, up from $0.53. Growth was driven by pricing and share buybacks, not patient volume, which declined. Costs rose in some areas, and the company reaffirmed its full-year EBITDA guidance of $280M-$300M.
2 min readPediatrix Medical Group (MD) officer Mary Ann E. Moore filed a Rule 144 notice to sell 21,335 shares, valued at $572,619.71, through Merrill Lynch on the NYSE. The shares stem from vested stock awards, with 81,253,271 shares outstanding as of September 11, 2026. Moore previously sold 9,260 shares in August 2026.
1 min readLinynsky Laura A sold (to issuer) 6,000 shares of Pediatrix Medical Group, Inc. (MD) at $26.82 ($0.16M total) on 2026-09-10.
1 min readPediatrix Medical Group (MD) director Laura Linynsky plans to sell 6,000 shares under Rule 144, acquired through stock plan activity. Merrill Lynch is the broker for the transaction, with the Form 144 notice signed on September 10, 2026.
1 min readPediatrix Medical Group (MD) has seen a 24.8% year-to-date stock price increase despite concerns over declining revenue and demand for its neonatal and pediatric healthcare services. The company's 1-year total shareholder return is 56.2%, though its 5-year return is down 23.05%. Analysts debate its valuation, with some suggesting it is 1% overvalued at $26.33, while others argue it is undervalued at $58.51. The company faces challenges from portfolio restructuring and rising salary costs.
2 min readMorgan Stanley downgraded Baidu (BIDU) to Underweight, cutting its price target to $80. CIBC downgraded Bank of Montreal (BMO) to Neutral, raising its target to C$272. JP Morgan downgraded Cogent Communications (CCOI) to Underweight, lowering its target to $9. Jefferies downgraded Pediatrix Medical Group (MD) to Hold, raising its target to $28. UBS downgraded Core Natural Resources (CNR) to Neutral, raising its target to $105.
2 min readPediatrix Medical Group (MD) shares fell 1.2% in pre-market trading after Jefferies downgraded the stock from Buy to Hold, citing limited upside potential. The firm raised its price target to $28 but noted shares are near their 52-week high. Jefferies highlighted the stock's 150% advance over two years and anticipated headwinds from Affordable Care Act changes. Pediatrix recently reported Q2 2026 earnings beating estimates but maintained its full-year EBITDA guidance.
1 min readYoung Sylvia Jean sold (to issuer) 18,500 shares of Pediatrix Medical Group, Inc. (MD) at $26.62 ($0.49M total) on 2026-08-14.
1 min readMidland Exploration Inc. (TSX-V: MD) said it and SOQUEM will start a follow-up exploration at the Malaco Mountain copper-gold-REE project in Quebec, including a 15-line km induced polarization survey plus prospecting and soil sampling. Midland cited 2025 grab-sample results up to 31.60% Cu and 6.92 g/t Au. The 2026 alliance budget is $1 million.
3 min readPediatrix Medical Group (MD) reported Q2 2026 revenue of $487.8 million, up 4% y/y, with adjusted EPS of $0.63 and adjusted EBITDA of $76.4 million. Net income was $39.8 million. Patient volume fell 2.1% y/y, while same-unit pricing rose 4%. CFO Rossi reaffirmed full-year 2026 adjusted EBITDA guidance of $280 million to $300 million.
6 min read
